sorry, we can't preview this file
Table_1_Drug Repurposing for Paracoccidioidomycosis Through a Computational Chemogenomics Framework.xlsx
Paracoccidioidomycosis (PCM) is the most prevalent endemic mycosis in Latin America. The disease is caused by fungi of the genus Paracoccidioides and mainly affects low-income rural workers after inhalation of fungal conidia suspended in the air. The current arsenal of chemotherapeutic agents requires long-term administration protocols. In addition, chemotherapy is related to a significantly increased frequency of disease relapse, high toxicity, and incomplete elimination of the fungus. Due to the limitations of current anti-PCM drugs, we developed a computational drug repurposing-chemogenomics approach to identify approved drugs or drug candidates in clinical trials with anti-PCM activity. In contrast to the one-drug-one-target paradigm, our chemogenomics approach attempts to predict interactions between drugs, and Paracoccidioides protein targets. To achieve this goal, we designed a workflow with the following steps: (a) compilation and preparation of Paracoccidioides spp. genome data; (b) identification of orthologous proteins among the isolates; (c) identification of homologous proteins in publicly available drug-target databases; (d) selection of Paracoccidioides essential targets using validated genes from Saccharomyces cerevisiae; (e) homology modeling and molecular docking studies; and (f) experimental validation of selected candidates. We prioritized 14 compounds. Two antineoplastic drug candidates (vistusertib and BGT-226) predicted to be inhibitors of phosphatidylinositol 3-kinase TOR2 showed antifungal activity at low micromolar concentrations (<10 μM). Four antifungal azole drugs (bifonazole, luliconazole, butoconazole, and sertaconazole) showed antifungal activity at low nanomolar concentrations, validating our methodology. The results suggest our strategy for predicting new anti-PCM drugs is useful. Finally, we could recommend hit-to-lead optimization studies to improve potency and selectivity, as well as pharmaceutical formulations to improve oral bioavailability of the antifungal azoles identified.
History
References
- https://doi.org//10.1093/nar/gks375
- https://doi.org//10.2174/0929867325666180309114824
- https://doi.org//10.1038/nrd1468
- https://doi.org//10.1021/ml300114c
- https://doi.org//10.1021/jm1014617
- https://doi.org//10.1093/nar/gku340
- https://doi.org//10.1038/nprot.2008.197
- https://doi.org//10.1038/nrg1317
- https://doi.org//10.1107/S0907444909042073
- https://doi.org//10.1038/448645a
- https://doi.org//10.1128/JCM.02914-12
- https://doi.org//10.1371/journal.pgen.1002345
- https://doi.org//10.1021/acs.jcim.6b00129
- https://doi.org//10.1002/jcc.24764
- https://doi.org//10.1091/mbc.5.1.105
- https://doi.org//10.1038/clpt.2013.1
- https://doi.org//10.1002/jcc.10128
- https://doi.org//10.1083/jcb.201406055
- https://doi.org//10.1016/j.drudis.2013.11.005
- https://doi.org//10.1208/s12248-018-0210-0
- https://doi.org//10.3389/fmicb.2017.00535
- https://doi.org//10.1016/0092-8674(93)90144-f
- https://doi.org//10.1093/nar/gkt1068
- https://doi.org//10.1093/nar/gkx1076
- https://doi.org//10.3390/jof3010001
- https://doi.org//10.1007/s10822-012-9584-8
- https://doi.org//10.1371/journal.pntd.0003435
- https://doi.org//10.1021/cr500098f
- https://doi.org//10.1016/j.tips.2013.03.004
- https://doi.org//10.1016/S1473-3099(17)30306-7
- https://doi.org//10.1093/nar/gks376
- https://doi.org//10.1093/nar/gku1214
- https://doi.org//10.1016/j.phrs.2015.10.021
- https://doi.org//10.1128/AAC.00925-15
- https://doi.org//10.2174/1568026616666160216154309
- https://doi.org//10.1590/S0036-46652015000700007
- https://doi.org//10.1590/0037-8682-0230-2017
- https://doi.org//10.2217/fmb-2018-0175
- https://doi.org//10.1093/nar/gkv487
- https://doi.org//10.1093/nar/gkh024
- https://doi.org//10.1093/nar/gkn858
CC BY 4.0